Enabling Precision Medicine with Automated Liquid Biopsy Solutions
Avant Genomics is enabling precise, accessible blood-based cancer detection through the automation of critical sample preparation steps in laboratories.
About Us
Avant Genomics, founded in early 2023 by two pioneering inventors from the University of Virginia's renowned microfluidics lab, is revolutionizing the future of cancer detection. Initially developed in the laboratory of Dr. James Landers, Avant Genomics is creating an advanced platform for automated liquid biopsy sample preparation, designed to enhance the detection of cancer from circulating tumor DNA.
Faster Results
By automating the laboratory workflows, the platform dramatically increases speed-to-result, ensuring quicker access to critical patient information.
Increased Efficiency
The platform optimizes laboratory workflows, cutting costs and minimizing the need for specialized expertise and manual intervention.
Greater Accuracy
Enhanced analytical performance provides more precise and reliable results, improving the quality of analytical outcomes.
Latest News
March 31, 2025
Avant Genomics Selected as TitletownTech Startup Combine Finalist
Avant Genomics has been selected as 1 of 7 finalists for the TitletownTech Startup Combine out of over 1,000 applicants!
Read MoreFebruary 27, 2025
Accepted into Commonwealth Bio Accelerator
The Avant Genomics team announced as one of the first of only a handful of companies to be accepted into the newly announced Commonwealth Bio Accelerator at their ribbon cutting!
Read MoreJanuary 14, 2025
Lisa Bowers Named Managing Director of UVA Enterprise Studio
Congratulations to our Chairwoman, Lisa Bowers, on her new appointment as the managing director of the UVA Enterprise Studio!
Read MoreAvant's Leadership Team
CEO and Co-Founder
Rachelle is a key technology inventor with a Ph.D. focused on microfluidic platforms for genetic applications. She has secured millions of dollars in non-dilutive funds for the R&D and commercialization of automated laboratory tools.
COO and Co-Founder
With a Ph.D. in analytical chemistry, Renna has developed multiple microfluidic technologies slated for rapid genetic analysis. Renna translates the company mission into a cohesive strategic plan.
CFO
Dan holds an MBA from the Darden School of Business and has 25 years of experience as a financial and operation executive, focusing on financial modeling, planning, and budgeting.
Board Chair
Lisa is the Managing Director of UVA's Enterprise Studio and has served as an executive and board member for biotech companies with successful exits (Day One Bio and DICE Therapeutics). Her executive successes followed a 16-year career at Roche/Genentech.
Partnership Opportunities
Strategic Partnerships
At Avant Genomics, we value strategic partnerships with corporate industry, academic and government research institutions, and hospital and reference laboratories. Collaboration drives innovation. We invite you to join us.
Explore PartnershipsInvestment Opportunities
Support our mission to enable precision medicine, beginning in the laboratory. We value investment partners who share our vision to bolster blood-based cancer detection and make this $11B global market accessible to patients everywhere.
Support Avant Genomics